Brachytherapy has the advantage of delivering a high dose to the tumor while sparing the surrounding normal tissues. With proper case selection and delivery technique, high-doserate (HDR) brachytherapy has great promise, because it eliminates radiation exposure, allows short treatment times, and can be performed on an outpatient basis. Additionally, use of a single-stepping source, allows optimization of dose distribution by varying the dwell time at each dwell position. However, when HDR brachytherapy is used, the treatments must be executed carefully, because the short treatment times do not allow any time for correction of errors, and mistakes can result in harm to patients. Hence, it is very important that all personnel involved in HDR brachytherapy be well trained and be constantly alert.
Introduction
Brachytherapy has the advantage of delivering a high dose to the tumor while sparing the surrounding normal tissues. Brachytherapy procedures were previously performed by inserting the radioactive material directly into the tumor ("hot" loading), thereby giving high radiation exposure to the physicians performing the procedure. Manually afterloaded techniques were introduced to increase accuracy and reduce the radiation hazards. In afterloaded techniques, hollow needles, catheters or applicators are first inserted into the tumor then loaded with radioactive materials. The introduction of remote controlled insertion of sources eliminated radiation exposure to visitors and medical personnel (1). In this technique, the patient is housed in a shielded room and the radiation therapist controls the treatment from outside the room. Hollow applicators, needles, or catheters are inserted into the tumor and connected by transfer tubes to the radioactive material, which is stored in a shielded safe within the HDR afterloader. The radiation source is driven through the transfer tubes and into the tumor by remote control (2-7). trolled brachytherapy (whether it is LDR, MDR, or HDR brachytherapy) eliminates the hazards of radiation exposure. The use of HDR has the added advantage that the treatments take only a few minutes, allowing them to be given on an outpatient basis with minimal risk of applicator movement and minimal patient discomfort. Additionally, use of a single-stepping source, as used in most modern HDR afterloaders, allows optimization of dose distribution by varying the dwell time at each dwell position. However, it should be emphasized that while optimization can improve the dose distribution, it should not be used to substitute for a poorly placed implant. Nag and Samsami (9) have provided examples of inappropriate optimization strategies, which can lead to suboptimal dosimetry plans and clinical problems. The advantages and disadvantages of HDR in comparison to LDR are enumerated in Table I. The advantages listed above have led to increased use of HDR worldwide; however, training and expertise is required for proper administration of these treatments. The American Brachytherapy Society (ABS) has recently published guidelines and recommendations for the use of HDR at various sites (10) (11) (12) (13) (14) (15) (16) (17) (18) . While this article summarizes the ABS recommendations, the reader should refer to the original publications for details. It should be noted that these guidelines are in evolution and on-going, controlled clinical trials are needed to critically evaluate the efficacy of these procedures.
How to Design a New HDR Protocol
Most radiation oncologists are familiar with LDR brachytherapy. LDR (at 30-50 cGy/hr) can be added to EBRT doses (at 2 Gy/day) to obtain equivalent total doses. HDR brachytherapy is a relatively new modality that is distinct from LDR brachytherapy, and radiation oncologists who are accustomed to LDR techniques must realize that experience in LDR cannot be automatically translated into expertise in HDR. It is important to review the current literature and survey the experiences of centers that have been performing HDR. When converting from LDR to HDR, one must keep the other parameters (chemotherapy, EBRT field/dose, dose-specification point, applicators, patient population etc) the same, changing only the LDR to HDR. Advantages Disadvantages 1. Radiation Protection • HDR eliminates radiation exposure hazard for care givers and visitors. Care givers are able to provide optimal patient care without fear of radiation exposure. • HDR eliminates source preparation and transportation.
• Since there is only one source, there is minimal risk of losing a radioactive source.
1. Radiobiological:
• The short treatment times do not allow for the repair of sublethal damage in normal tissue, or the redistribution of cells within the cell cycle or reoxygenation of the tumor cells; hence, multiple treatments are required.
Allows shorter treatment times:
• There is less patient discomfort since prolonged bed rest is eliminated. • It is possible to treat patients who may not tolerate long periods of isolation and those who are at high risk for pulmonary embolism due to prolonged bed rest. • There is less risk of applicator movement during therapy.
• There are reduced hospitalization costs since outpatient therapy is possible. • HDR may allow greater displacement of nearby normal tissues (by packing or retraction) which could potentially reduce morbidity. • It is possible to treat a larger number of patients in institutions that have a high volume of brachytherapy patients but insufficient inpatient facilities (e.g., in some developing countries). • Allow intraoperative treatments, which are completed while patient is still in the operating room.
Limited experience:
• Few centers in the United States have long-term (greater than 20 years) experience. • Until recently, standardized treatment guidelines were not available; however, the American Brachytherapy Society (ABS) has recently provided guidelines for HDR at various sites (10-18).
3. HDR sources are of smaller diameter than the Cesium sources that are used for intracavitary LDR:
• This reduces the need for dilatation of the cervix and therefore reduces the need for heavy sedation or general anesthesia. • High-risk patients who are unable to tolerate general anesthesia can be more safely treated. • HDR allows for interstitial, intraluminal and percutaneous insertions.
The economic disadvantage:
• The use of HDR brachytherapy as compared to manual afterloading techniques, requires a large initial capital expenditure since the remote afterloaders cost about $300,000. • There are additional costs for a shielded room and personnel costs are higher as the procedures are more labor intensive.
4. HDR makes treatment dose distribution optimization possible.
• Variations of the dwell times of a single stepping source allow an almost infinite variation of the effective source strengths, and the source positions allows for greater control of the dose distribution and potentially less morbidity.
Fractionation schemes for HDR are widely variable and many radiation oncologists are not very familiar with the resultant biological effects. Empirical methods such as the NSD (nominal standard dose), TDF (time-dose factor), or a dose reduction factor of 0.6 have been used in the past to convert HDR doses to LDR equivalent doses. The linearquadratic (LQ) equation (23) can be used to guide development of HDR doses and fractionation schedules. However, the LQ mathematical calculations are tedious and may not be practical on a day-to-day basis. Hence, a simplified computer program was developed by Nag and Gupta (24) to obtain the biologically-equivalent doses for HDR. The clinician needs only to enter the EBRT total dose and dose/fraction, HDR dose, and the number of HDR fractions. The computer program will automatically calculate the equivalent doses for tumor and normal tissue effects. Equivalent doses are expressed in clinically familiar terms (as if given at 2 Gy per fraction) rather than as biologically equivalent doses (BED), which are unfamiliar to clinicians. Furthermore, a dose-modifying factor (DMF) is applied to the normal tissues to account for the fact that doses to normal tissues are different from the doses to the tumor, thus providing a more realistic equivalent normal tissue effect. This program can be used to determine HDR doses that are equivalent to LDR brachytherapy doses used to treat various cancers. Alternatively, the program may be used to express the equivalent dose of different HDR dose-fractionation regimes as shown for cervical cancer in Table II . It is remarkable that the equivalent doses for tumor effects for the various fractionation regimes used for early-stage cervical cancers are so similar, ranging from 82-85 Gy while those used for advanced cancers are about 90 Gy (Table II) . The equivalent dose for normal tissue late-effects depends on the assumed DMF (0.6, 0.7 or 0.9). For the fractionation scheme shown in Table II , row 1, the equivalent late effect on normal tissue (bladder or rectum) would be 59.5, 71, or 98 Gy, respectively if the doses to normal tissues were 60%, 70%, or 90% of the prescribed dose to point A.
Although the LQ biomathematical model can be helpful in determining equivalent doses, it has many limitations that must be kept in mind when using the program. The LQ model accounts for the repair of sublethal damage and does not account for reoxygenation of hypoxic cells, reassortment within the cell cycle, or repopulation of tumor cells. These factors are generally small under normal circumstances. However, large doses per fraction do not allow reoxygenation of hypoxic tumor cells or reassortment of tumors from radioresistant S-phase. Hence, a large radiation dose will preferentially kill radiosensitive cells, leaving a high number of hypoxic, radioresistant cells. Therefore the computer program will overestimate the tumor effect of a single large dose per fraction (unless a resensitization factor is introduced).
The LQ equation does not take into account the proliferation of tumor cells. This factor is small if the treatments are performed over a short duration. However, if the treatments are highly protracted (e.g., there is a long time interval between EBRT and HDR), or in cases of tumors with high proliferation rates, the LQ model will overestimate the actual tumor effect. It also must be noted that individual α/β values are very variable. The α/β values for early reactions vary from 6-13 (the default in the program is set at 10); the α/β values for late reactions vary from 1-7 (default being set at 3), while α/β values for tumors vary from 0.4 -13 (the default being set at 10). However, α/β values for a particular patient is not known and may vary even within same tissue. The equivalent doses obtained will therefore depend on the α/β values used for that particular calculation. The LQ model assumes complete repair between fractions. If the time interval between fractions is too short (<6 hours) or the half-time of repair is very long, the repair of normal tissues will be incomplete, and the LQ formula will underestimate the biological effect. Hence it is important to have sufficient time interval (at least 6 hours) between treatment fractions.
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The infinite variation of the dwell times that is possible with HDR (or PDR) allows better optimization of the doses than can be achieved with LDR. Better packing or retraction of normal tissues is possible with HDR, due to the short treatment duration. This factor is not usually taken into account in the LQ model (unless the DMF is altered). Another difference not accounted for in the LQ model is that the dose stated in brachytherapy is generally the minimum tumor dose. The doses within the tumor are much higher. Hence the effective dose (for tumor control probability) is much higher for brachytherapy than for EBRT.
In view of the many limitations of the LQ model, it must be stressed that, as with any mathematical model, the LQ model should be used judiciously as a guide only and should always be correlated with clinical judgment and outcome results. Caution is especially warranted whenever large fraction sizes are used, since their clinical results have not been well studied.
Common Uses of HDR Brachytherapy
Although HDR brachytherapy has been used in almost every site in the body, it is most commonly used to treat cancers of the cervix, endometrium, lung, and esophagus (19). Less common treated sites for HDR include the prostate, bile duct, breast, brain, rectum, head & neck, skin, soft tissues and blood vessels (coronary and peripheral arteries). HDR is generally used as a component of multi-modality treatment that includes external beam radiation therapy (EBRT) and/or chemotherapy and surgery. A summary of the clinical uses of HDR at various sites is included this article.
Carcinoma of the Cervix
Brachytherapy is a necessary component in the curative treatment of cervical cancers (10, 11). HDR has gained popularity in the U.S. over the last decade due the advantages alluded to earlier, specifically the possibility of therapy on an outpatient basis, avoidance of long-term bed rest, and avoidance of cervical dilation. Additionally greater sparing of the rectum and bladder by temporary retraction, dose optimization, and integration with EBRT to the pelvis are possible. These advantages must be counterbalanced with the greater number of treatments required (typically 5 or 6 treatments lasting approximately 10-15 minutes each).
The ABS recommends keeping the total duration of treatment (EBRT and HDR) to less than 8 weeks since prolongation adversely affects local control and survival (11). Because the overall treatment duration would be unduly prolonged if HDR treatments (generally 5 or 6 fractions) were begun after completion of EBRT, the HDR is inter-digitated during the course of EBRT. The combined EBRT and HDR dose to Point A (or Point H) is an LDR equivalent of 80-85 Gy for early stage disease and 85-90 Gy for advanced stage (11). Early disease is defined as non-bulky stage I/II <4 cm in diameter; advanced diseased is defined as stage I/II >4 cm in diameter or stage IIIB. The pelvic sidewall dose recommendations are 50-55 Gy for smaller lesions and 55-60 Gy for larger ones. Although there is marked variation in the dose and fractionation employed for cervical HDR (10, 20, 21), most centers use a schedule of about 6-8 Gy per fraction in 4-6 fractions (a smaller number of fractions is used by those using larger doses per fraction) (20, 22) . The HDR dose is also dependent on the stage of the disease and the dose of EBRT.
HDR doses can be obtained from the LDR equivalent using the linear-quadratic equation (23). Because of the dose rate effect in HDR, the total physical dose will be lower for HDR than for LDR brachytherapy. Because conversion of HDR doses to LDR equivalent doses mathematically may not be practical on a day-to-day basis, a simplified computer program (24) can be used to obtain the equivalent dose. While recognizing that many efficacious HDR fractionation schedules exist, the ABS suggestions and the equivalent doses are given in Table II as a guide. The recommended HDR dose per fraction may vary by ±0.25 Gy. It is emphasized that extra care must be taken to ensure adequate bladder and rectal packing if high dose (>7 Gy) per fraction is used.
In certain difficult clinical situations (e.g., a narrow fibrotic vagina, bulky tumors, the inability to enter the cervical os, extension to the lateral parametria or pelvic sidewall, lower vaginal extension and suboptimal applicator placement) the normal tissue tolerance may be exceeded if the above doses are used. In these situations, the HDR fraction size can be decreased (which requires an increase in the fraction number), or the EBRT dose increased while decreasing the HDR total dose. Alternatively, an interstitial implant (either LDR or HDR) may be used instead.
LDR brachytherapy has been used with good results in carcinoma of the cervix for almost 100 years. Hence, it is important to critically analyze whether the results obtained with HDR brachytherapy, which has a much shorter history, compare with those obtained with LDR. Unfortunately, most of the published reports have been non-randomized studies. The earlier studies showed good local control and survival rates that compared well to those obtained with LDR; however, initially some increased late complications were noted (25). Subsequent results of randomized trials, multi-institutional meta-analyses, and single institutional reviews, which used lower dose per fraction and a greater number of fractions, showed that survival, local control, and morbidity of HDR treatments were equivalent to that of LDR without increased morbidity (26-35).
Two meta-analyses have compared HDR with LDR brachytherapy. Orton compared the published results of HDR brachytherapy in treating 4283 patients with the results of LDR in 5100 patients (24, 33) . The overall 5 year survival rates were 61.2% for HDR and 55.5% for LDR. Statistically quantifiable conclusions cannot be drawn from comparisons of the results of uncontrolled studies using different methodologies from various centers; however, this anecdotal evidence suggests that the results of HDR are at least as good as those achieved by LDR brachytherapy. The incidence of severe complications with HDR was 3.5% compared to 7.7% with LDR (24, 33). Fu and Phillips (22) reached a similar conclusion in their worldwide review.
Two randomized studies have compared the use of HDR with the use of LDR brachytherapy in carcinoma of the cervix (34, 35) . In the first, Shigematsu et al., reported on 143 patients treated with HDR brachytherapy compared to 106 patients treated with LDR for stage IIB and III disease. Although the randomization technique was suboptimal (i.e., some patients who were randomized to LDR were actually treated with HDR because of limited LDR availability) the HDR arm achieved superior local control with no difference in survival as compared to the LDR arm (34). In a randomized study of LDR versus HDR brachytherapy reported from India (35), there was no difference in local control, survival, or severe complications between the two treatment modalities in 482 patients. However, there was a statistical difference in rectal complications, with a 20% rate in the LDR group and only a 6% rate in the HDR group. In summary, although large, multi-institutional, randomized trials are not available, the available data from single-institution, randomized trials, retrospective analyses and meta-analyses suggests that survival, local control, and morbidity of HDR treatments are probably equivalent to that of LDR. There is controversy regarding the best method. Pelvic EBRT, vaginal vault brachytherapy or a combination can be used depending on the extent of pelvic lymph node dissection and whether chemotherapy will be added. EBRT has the advantage of irradiating the pelvic lymph nodes, but takes about 5 weeks to perform and has some morbidity. Brachytherapy is more convenient, has low morbidity, but does not treat the lymph nodes. Hence, some centers combine both EBRT and brachytherapy, although it has not been proven that the combination yields any superior results. Others prefer "watchful waiting" and use salvage irradiation if there is a recurrence, since the final survival rate is not compromised. However, in cases of recurrence, a combination of pelvic EBRT and brachytherapy is required.
Carcinoma of the Endometrium
If pelvic EBRT is used, the dose is usually 40-45 Gy in 20-25 treatments with midline shielding after about 40 Gy (12). A vaginal cylinder is commonly used to deliver HDR brachytherapy. The largest diameter cylinder that comfortably fits the vagina should be used to increase the depth dose. The length of vaginal vault treated varies. Some treat the superior 3 or 5 cm, while others treat the superior half or two-thirds of the vagina (12, (36) (37) (38) (39) (40) . For serous and clear cell histologies, treatment of the entire vaginal canal should be considered. The dose distribution should be optimized to deliver the prescribed dose either at the vaginal surface or at 0.5 cm depth, depending on the institutional policy. Regardless of the prescription point, doses to both of these points should be reported (12). The ABS dose suggestions (12) for HDR alone or in combination with 45 Gy EBRT are given in Table III . Since some institutions specify the dose to the vaginal surface and others specify the dose at 0.5-cm depth, suggested HDR doses have been given for both specification methods.
The five-year survival rates of HDR therapy vary from 72% to 97%, depending on the stage, grade, and depth of myometrial invasion (36-42). The severe (Grade III or IV) late complication rate is usually <1% and depends on the dose per fraction (36, 40, 41) . The incidence of vaginal shortening is also very much dose dependent, reportedly as high as 70% when 9 Gy per fraction was prescribed at 1 cm depth to 31% when the dose was reduced to 4.5 Gy per fraction (40). Other factors that increase morbidity include the use of a small (2 cm) diameter vaginal cylinder, the addition of pelvic external beam radiation, and dose specification point beyond 0.5 cm (36).
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A combination of pelvic EBRT and brachytherapy is generally used to treat recurrences at the vaginal cuff. With distal vaginal recurrences, the entire vagina and medial inguinal nodes are included in the EBRT field. Intracavitary vaginal brachytherapy should be used only for non-bulky recurrences (thickness <5 mm after the completion of EBRT) (12). Interstitial brachytherapy is to be used for bulky recurrences (thickness > 5 mm after the completion of EBRT) and for previously irradiated patients.
The ABS suggested doses for HDR brachytherapy (in combination with 45 Gy EBRT) are provided in Table IV (12) .
Patients with adenocarcinoma of the endometrium who are not candidates for surgery because of severe medical problems are treated with radiation therapy. A combination of pelvic EBRT beam and brachytherapy is preferred whenever possible. However, many of the conditions that do not allow surgery in these cases are also relative contraindications for EBRT and for LDR brachytherapy. These patients may be treated with HDR alone.
Numerous applicators can be used for treatment of primary endometrial cancer. A tandem and colpostat is often used; however, this applicator will not irradiate the uterine surface homogeneously. Others have used a curved tandem, turning it to the left and right in alternate insertions. A "Y" shaped applicator irradiates the fundus more evenly. Other possibilities include modified Heyman capsules or multiple tandems. The dose is commonly specified at 2.0 cm from the source, although CT-based treatment planning to ensure a more homogeneous dose to the entire myometrium is preferred. The dose per fraction has ranged from 5-12 Gy, and 4-6 fractions are commonly employed (37, 41, (43) (44) (45) (46) (47) (48) . The dose and/or the dose per fraction is reduced if EBRT can be added. The ABS suggested doses for HDR brachytherapy alone or in combination with 45 Gy EBRT are given in Table   V (12) . The survival at 5 years for stage I is about 70% to 80%, which is slightly lower than that obtained by surgery. The toxicity is higher (about 7%) when patients are treated with high doses per fraction (44, 47, 49) .
Endobronchial Radiation
The use of HDR brachytherapy is well established for palliation of cough, dyspnea, pain, and hemoptysis in patients with advanced or metastatic lung cancer. The use of brachytherapy as a boost to EBRT in curative cases should be restricted to a select group of patients who have predominantly endobronchial disease, are medically inoperable, or have small/occult carcinomas of the lung.
An initial bronchoscopy is performed to evaluate the airway and locate the site of obstruction. Either a 5 or 6-French catheter (inserted through the brush channel of the bronchoscope) can be used to deliver the brachytherapy. The length to be irradiated usually includes the endobronchial tumor and 1.0-2.0 cm proximal and distal margins. If a single catheter is used and there is minimal curvature of the catheter in the area to be irradiated, it is possible to minimize the treatment planning time by using pre-planned dosimetry. For example, Ohio State University has pre-calculated treatment plans for 3, 5, 7, and 10 cm lengths to be irradiated to 5 or 7. extrinsic tumors that compress the bronchus or the trachea. Endobronchial brachytherapy can generally give quicker palliation of obstruction than EBRT. Furthermore, brachytherapy can be more convenient than 2 to 3 weeks of daily EBRT.
II. Patients who are unable to tolerate any EBRT because of poor lung function.
III. Patients with previous external beam radiation therapy (EBRT) of sufficient total dose to preclude further EBRT.
A variety of doses have been successfully used by various centers. Total doses ranging from 15 Gy to 47 Gy HDR in 1 to 5 fractions calculated at 1.0 cm have been reported (51, 53). The ABS suggests using three weekly fractions of 7.5 Gy each or 2 fractions of 10 Gy each or 4 fractions of 6 Gy each prescribed at 1.0 cm when HDR is used as the sole modality for palliation (15). These fractionation regimes have similar radiobiological equivalence using the linear quadratic model (24), and there is no evidence of superiority for one regime over the other. The benefits of fewer bronchoscopic applications should be weighed against the risks of higher dose per fraction. Additional treatments or doses higher than those suggested can be considered for unirradiated patients or those who have received limited radiation. When HDR is used as a planned boost to supplement palliative EBRT of 30 Gy in 10-12 fractions, the ABS suggests using 2 fractions of 7.5 Gy each or 3 fractions of 5 Gy each or 4 fractions of 4 Gy each (prescribed at 1.0 cm) in patients with no previous history of thoracic irradiation (15) . The interval between fractions is generally one to two weeks. The brachytherapy dose should be reduced when aggressive chemotherapy is given. Concomitant chemo-therapy should be avoided during brachytherapy, unless it is in the context of a clinical trial.
The results from various centers (summarized in Table VI) show clinical improvement from 50% to 100% and bronchoscopy response from 59% to 100% (55-65, 50). Comparison of these results is difficult because of the differences in patient population and the variability in dose and fractionation employed. Radiation bronchitis and stenosis may occur after endobronchial brachytherapy (66), necessitating close follow-up.
Another more serious complication is fatal hemoptysis. The hemoptysis could be a radiation therapy complication result- The ABS suggests an HDR dose of three 5 Gy fractions or two 7.5 Gy fractions as a boost to EBRT (either 60 Gy in 30 fractions or 45 Gy in 15 fractions) (15). The HDR dose should be prescribed at a distance of 1.0 cm from the central axis of the catheter and given weekly. If endobronchial brachytherapy is used alone (in previously unirradiated patients), HDR doses five 5 Gy fractions or three 7.5 Gy fractions prescribed to 1 cm may be used (15).
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Cancer of the Esophagus
The results of treatment for advanced cancer of the esophagus are dismal (5 year survival = 6%); hence, treatment is essentially palliative. HDR brachytherapy can used either alone or in combination with EBRT in the treatment of esophageal cancer (78-86). Brachytherapy is relatively simple to perform, since a single catheter is used for the treatment. A nasogastric tube or a specially designed esophageal applicator is used to deliver the treatments. The largest diameter applicator that can be inserted easily (either intraorally or intranasally) should be used to minimize the mucosal dose relative to the dose at depth. The site to be irradiated, which includes the tumor and a margin of 2-5 cm, can be confirmed by fluoroscopy or endoscopy. The ABS recommends an HDR dose of 10 Gy in 2 fractions, prescribed at 1 cm from the source, to boost 50 Gy EBRT (84). HDR brachytherapy can be given before, concurrently with, or after EBRT. The advantage of giving brachytherapy after EBRT is that a more uniform dose can be delivered to the residual tumor after it has been reduced by EBRT. Brachytherapy given initially provides rapid relief of dysphagia. HDR brachytherapy at doses of 16 Gy in 2 treatments have been used without additional EBRT to palliate esophageal cancers (85, 86) .
Retrospective studies as well as prospective, randomized clinical trials show that there is improved local control and survival when HDR brachytherapy is added to EBRT and that HDR brachytherapy alone can be used for palliation of advanced esophageal cancers (78-86). Since a high dose is delivered to the esophageal mucosa, side effects may include ulcerations, fistulae, and esophageal strictures.
Yin et al., from Shanxi Cancer Hospital, have shown in a randomized trial that results of EBRT combined with brachyther- apy were better than those of EBRT alone in cancer of the esophagus (78, 79). One hundred patients were treated in the EBRT alone arm and given 70 Gy in 35 fractions over a period of seven weeks. One hundred patients in the second arm received EBRT of 50 Gy in 25 fractions followed by HDR brachytherapy of 6.54 Gy per week for 3 or 4 applications using Cesium-137. EBRT combined with brachytherapy gave survival results of 78%, 31%, and 17% at 1, 3, and 5 years respectively, compared to 56%, 19%, and 10% for EBRT alone. The improvements were statistically significant for 1 and 3 year survival data, but not for 5 year survival data. Sur et al., (80) reported a randomized trial of 50 patients with squamous cell carcinoma of the esophagus. The group receiving EBRT alone (35 Gy in 15 treatments) had a 12-month survival of 16% compared to 69% in the group receiving 35 Gy EBRT followed by 12 Gy in 2 fractions of HDR brachytherapy. There was a statistical improvement in the relief of dysphagia with the addition of HDR brachytherapy at 3 months (82% versus 24%), and at 6 months (84% versus 13%).
A multi-center, prospective randomized study conducted under the auspices of the International Atomic Energy Agency (IAEA) evaluated two HDR regimens in 232 patients (86). Patients were randomized to receive 18 Gy/3 fractions/alternate days (Group (Gr) A -112 patients) or 16 Gy/2 fractions/alternate days (Gr B -120 patients). The HDR dose was prescribed at 1 cm from the center of the source axis. The dysphagia-free survival for the whole group was 7.1 months (mo) (Gr A=7.8 mo, Gr B=6.3 mo, p>0.05). The overall survival was 7.9 month for the whole group (Gr A=9.1 mo, Gr B=6.9 mo, p>0.05). The incidence of strictures (Gr A=12, Gr B=13, p>0.05) and fistulae (Gr A=11, Gr B=12, p>0.05) was similar in both groups. The authors concluded that dose fractions of 6 Gy × 3 and 8 Gy × 2 within one week give similar results for dysphagia-free survival, overall survival, strictures, and fistulae.
Carcinoma of the Prostate
Currently, permanent implantation of iodine-125 or palladium-103 seeds is the most common type of prostate brachytherapy. However, several centers have used HDR brachytherapy usually as a boost to EBRT (87-95) for the treatment of prostate cancer with encouraging results. One of the major advantages of HDR is that the dose distribution can be intraoperatively optimized by varying the dwell times at various dwell positions (96), potentially allowing reliable and reproducible delivery of the prescribed dose to the target volume while keeping the doses to normal structures, i.e., rectum, bladder, and urethra, within acceptable limits. Another potential advantage of HDR brachytherapy in prostate cancer is the theoretical consideration that prostate cancer cells behave more like late reacting tissue with a low alpha-beta ratio and they should, therefore, respond more favorably to higher dose fractions rather than to the lower dose rate delivered in LDR brachytherapy (97, 98) .
Standard fractionation EBRT (39.6 to 50.4 Gy) is given concurrent with, or within 2 weeks before or after HDR brachytherapy. The minimum volume treated should include the entire prostate and seminal vesicles with margin, with or without pelvic lymph nodes. The HDR dose is given in multiple fractions in one or two implant procedures. A variety of dose and fractionation schemes may be appropriate for same-stage disease (Table IX) (87, (89) (90) (91) (92) (93) (94) . The ABS dose suggestions for HDR brachytherapy as a boost to EBRT depend on risk groups as shown in Table X (17) . The HDR fractions are generally given twice a day with a minimum of 6 hours between fractions. The most commonly encountered acute genito-urinary (GU) morbidities include urinary irritative symptoms, hematuria, hematospermia, and/or urinary retention, similar to LDR permanent implants.
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Biliary Cancers
Tumors of the bile duct are often unresectable and are treated palliatively by biliary drainage and EBRT. The biliary drainage tube can be accessed to provide brachytherapy to the area of obstruction [either by LDR, 100) or by HDR brachytherapy (101-103)] alone or in combination with EBRT. Although brachytherapy is commonly delivered through a transhepatic cholangiogram catheter (101), it has also been delivered using an endoscopic retrograde technique (102). A size 12-French biliary drainage catheter is required to accommodate a 6-French HDR brachytherapy catheter. Therefore, the indwelling biliary drainage catheter is upsized to a size 12-French biliary drainage catheter, if required. Under fluoroscopy, the brachytherapy catheter is inserted into the biliary drainage catheter and advanced past the area of obstruction. A Tuohy-Borst (Y-shaped) adapter attached to the end of the biliary catheter allows concurrent external biliary drainage while holding the HDR catheter in place. The area of the obstruction is irradiated along with 1 to 2 cm proximal and distal margins. The dose per fraction delivered is variable, but about 5 Gy per fraction at a distance of 1 cm from the source is commonly used for 3-4 fractions (15-20 Gy total) to boost 45 Gy EBRT (103). If EBRT is not delivered, a palliative dose of 30 Gy in 6 fractions can be used (103).
Concurrent chemotherapy (5-FU) is often added. It is important to leave the biliary drainage catheter in place after therapy to minimize biliary stricture.
Head and Neck Cancers
Brachytherapy, especially using manually afterloaded iridium-192, has been widely used to treat head and neck cancers. HDR brachytherapy has been used in selected cases to reduce radiation exposure and permit optimization as summarized in Table XI (16, (104) (105) (106) (107) (108) (109) . However, these advantages are offset by the need for multiple fractionation since the head and neck area does not tolerate high doses per fraction. The nasopharynx is a site within the head and neck area that is easily accessed by an intracavitary HDR applicator (110, 111) . Doses of 18 Gy in 6 fractions are delivered by a special nasopharynx applicator to boost 46-60 Gy of EBRT (111).
The use of HDR brachytherapy catheters incorporated in removable dental molds allows repeated, highly reproducible, fractionated outpatient brachytherapy of superficial (less than 0.5 cm thick) tumors without requiring repeated catheter insertion into the tumor (112). Suitable sites for mold therapy include the scalp, face, pinna, lip, buccal mucosa, maxillary antrum, hard palate, oral cavity, external auditory canal and the orbital cavity after exenteration. HDR can be used as the sole modality or in conjunction with EBRT. A total HDR dose equivalent to about 60 Gy LDR (prescribed at 0.5 cm depth) is recommended when used as the sole modality (16). The HDR can also be used as a boost to 45-50 Gy EBRT, in which case, the HDR doses are appropriately reduced to LDR equivalent doses of 15-30 Gy. The actual HDR dose per fraction and number of fractions can be varied to suit individual situations (including site and treatment volume). Biomathematical (linear-quadratic) modeling can be used to assist in the conversion of LDR to HDR (24).
Another innovative approach is the use of intraoperative HDR brachytherapy, which permits normal tissues to be retracted or shielded during brachytherapy. Intraoperative HDR brachytherapy can reach many sites in the head and neck area that are difficult to treat or are inaccessible by either LDR brachytherapy or intraoperative electron beam radiation. The catheters are removed immediately after the single dose of radiation, hence, minimizing inconvenience and permitting the use of brachytherapy in areas such as the base of skull (113). Doses of 7.5-15.0 Gy are given when EBRT of 45-50 Gy can be added. In recurrent tumors where no further EBRT can be given, a single intraoperative dose of 15-20 Gy can be given.
Nag
Soft Tissue Sarcomas
Excellent results are obtained with a combination of wide excision of the tumor and adjuvant EBRT. However, irradiation of large volumes after surgery gives rise to morbidity, especially normal tissue fibrosis. To minimize morbidity, a few centers have used LDR brachytherapy, either alone (114) or with EBRT (115). A prospective randomized trial showed superior local control (80% at 5 years) in the group receiving brachytherapy versus 62% in the group not receiving brachytherapy (114). The major problem with LDR brachytherapy of large volumes is the radiation exposure involved. Hence, a few centers are investigating the use of HDR brachytherapy for soft tissue sarcomas (116) (117) (118) (119) (120) (121) . HDR brachytherapy catheters are implanted along the tumor bed and radio-opaque clips indicate the margins. A 2-5 cm margin proximally and distally is used after gross excision of tumor.
Optimized treatment planning can be used to deliver a more homogeneous dose. Doses of 40-50 Gy are given in 12-15 fractions if the HDR is given alone (116, 117) . If EBRT (45-50 Gy) is added, the brachytherapy dose is limited to 18-25 Gy in 4-7 fractions) (122). It is important to delay the start of brachytherapy for about 4-7 days to allow for wound healing (14) . Nerve tolerance to high dose per fraction is poor and HDR should be used with caution when catheters have to be placed in contact with neurovascular structures. Interventions to minimize morbidity in soft tissue sarcomas are provided in Table XII (14) . Outcome of non-randomized studies using HDR doses in the range of 3-9 Gy per fraction given once or twice daily are outlined in Table XIII (116) (117) (118) (119) (120) (121) .
Pediatric Tumors
LDR brachytherapy has been used in children to reduce the deleterious effects of EBRT (123-125). However, LDR brachytherapy is difficult to perform in young children and infants because they require prolonged sedation and immobilization with close monitoring, which increases the risk of radiation exposure to nursing staff and parents. HDR is therefore very appealing in infants and younger children and is currently undergoing trials at Ohio State University (126-128). The recommended dose for HDR as monotherapy is 36 Gy in 12 fractions given at 3 Gy (prescribed at 0.5 cm) twice a day (14, 128) . The interval between fractions is at least 6 hours. There are no published data giving any dose recommendations for HDR as boost to EBRT. The linear-quadratic model (24) can be used to calculate a fractionation scheme equivalent to that of an LDR implant boost-dose of 15-25 Gy (prescribed at 0.5 cm). The recommended dose for intraoperative HDR brachytherapy as a boost to EBRT is 10-15 Gy (prescribed at 0.5 cm), depending on the extent of residual disease (129) (130) (131) (132) (133) . According to the Inter-group rhab- 1. Delay radioactive loading until after the fifth postoperative day for patients treated with monotherapy.
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2. Minimize dose to normal tissues (e.g., gonads, breasts, thyroid, skin) whenever possible, especially in children and patients of childbearing age. 3. Minimize the dose to the surrounding organs by using temporary iodine-125 implant (which has lower energy) instead of iridium-192 implant. 4. Limit the allowable skin dose -the 40 Gy isodose line (LDR) to less than 25 cm 2 and the 25 Gy isodose line to less than 100 cm 2 . domyosarcoma study (IRS) the standard EBRT dose for pediatric soft tissue sarcoma is 40 Gy for microscopic disease and 50 Gy for gross disease. IOHDR allows reduction in the dose of EBRT to 27-30 Gy so that concerns for impaired growth and organ function is greatly reduced (128, 129, 134) . The results of HDR brachytherapy in the treatment of pediatric tumors are summarized in Table XIV (129, 130, 132, 133, 135) . Although the long-term morbidity of HDR brachytherapy in young children is not fully known, one may expect preservation of organ functions similar to the that seen with LDR brachytherapy (123). Due to the complexities involved in pediatric HDR brachytherapy, it is recommended that the use of HDR brachytherapy in pediatric tumors be limited to centers that have experience with pediatric implants (14).
Breast Cancer
EBRT is the standard radiation modality used after lumpectomy in the conservative management of breast cancer. Brachytherapy has been used to boost the EBRT dose in select high-risk patients (136) (137) (138) (139) .
Additionally, brachytherapy has been used as the sole modality of treat-ment (140-144) to decrease the 6-week treatment duration required for a course of EBRT to about 5 days. Table XV lists the patients in whom an accelerated (4-5 days) brachytherapy treatment course can be an attractive alternative to six weeks of EBRT (13). These criteria have been recommended to avoid potential toxicity and to limit the risk of microscopic disease outside the target area. Tumor size limitations were given because the size of the implanted area required to cover a 1-2 cm margin around a lumpectomy cavity created with the removal of a tumor >3 cm would be impractical in most patients. Axillary nodal involvement has an unclear impact on failure patterns in the intact breast after lumpectomy. Extrapolating from evidence that there is a survival benefit after chest wall radiotherapy in those with positive nodes at the time of modified radical mastectomy, it appears appropriate (until additional data is available) to only include those women with negative axillary nodes when considering partial breast treatment. The ABS recommends a total dose of 34 Gy in 10 fractions to the Clinical Target Volume (CTV) when HDR brachytherapy is used as the sole modality (13). The HDR treatments of 3.4 Gy are generally given at two fractions per day separated by at least 6 hours. 
Indications for brachytherapy as the sole modality
Selection criteria for brachytherapy as the sole modality Indications for brachytherapy as a boost to EBRT 1. The patient lives a long distance from radiation oncology treatment facilities. 2. The patient lacks transportation. 3. The patient is a professional whose schedule will not accommodate a six week course of therapy. 4. The patient is elderly, frail, or in poor health and therefore unable to travel for a prolonged course of daily treatment. 5. The patient's breasts are sufficiently large that they may have unacceptable toxicity with EBRT.
1. All patients should be appropriate candidates for standard breast conservation therapy 2. Unifocal, invasive ductal carcinoma 3. <3 cm in size. 4. Negative microscopic surgical margins of excision. 5. Axillary node negative by level I/II axillary dissection or sentinel node evaluation.
1.
For patients with close, positive, or unknown margins.
2.
For patients with extensive intraductal component (EIC).
3.
For younger patients.
4.
For deep tumor location in a large breast.
5.
For CTV of irregular thickness.
EBRT = external beam radiation therapy; CTV = clinical target volume;
This was also the dose used in a Phase II RTOG trial (141).
The results of HDR brachytherapy as the sole modality are included in Table XVI (140, (142) (143) (144) (145) . The ABS had originally recommended in 2001 that the use of brachytherapy as the sole modality should be performed in the context of a controlled clinical trial (13). After review of recent data, the consensus of the ABS has been modified to now state that accelerated partial breast irradiation can be offered as an alternative to whole breast irradiation in appropriately selected patients (18) . Depending on the selection criteria, final pathologic assessment is necessary to completely evaluate a patient for partial breast brachytherapy, and therefore the ABS does not advocate intraoperative treatment delivery at this time (18). Phase III protocols are required to further define the most appropriate candidates for breast brachytherapy as a sole modality treatment.
Because brachytherapy can deliver a higher dose to the CTV with a lower dose to the skin, it has the potential for an improved cosmetic result. However, its use as a boost after EBRT to the whole breast remains controversial. A randomized trial from Lyon demonstrated a small but statistically significant improvement in local control with the addition of a boost (137). Another randomized trial from Nice showed improvement in local control, but this difference was not statistically significant (138). Other reports have not shown any improvements with a brachytherapy boost (136). Because brachytherapy is an invasive procedure, it should be used selectively as a boosting technique. Situations in which brachytherapy may be advantageous as a boost are listed in Table XV . The brachytherapy boost can be given before or after EBRT, usually with a 1-2 week gap between EBRT and brachytherapy. Data on the use of HDR as a boost are limited (Table XVI) 
Discussion
Brachytherapy has gradually evolved over the past century. Initially, it was performed by inserting the radioactive sources directly into the tumor ("hot" loading), which exposed personnel to high doses of radiation, and hence, brachytherapy did not gain much popularity. Manual afterloaded procedures, in which hollow catheters are initially inserted into the tumor and then loaded with radioactive materials after proper positioning, significantly reduced radiation exposure to personnel. In remote afterloading, an operator outside the room loaded the radioactive material into the catheters by remote control. In HDR brachytherapy the elimination of the radiation exposure and the short treatment times allow for outpatient brachytherapy. Intraoperative High Dose Rate Brachytherapy (IOHDR) allows a single dose of radiation to be delivered during surgery (147, 148, (152) (153) (154) . Doses of 10-20 Gy are usually given as a single fraction over 10-60 minutes (153, 154) . The advantages of intraoperative HDR brachytherapy over perioperative brachytherapy or electron beam IORT are listed in Table  XVII . Unfortunately, the relative scarcity of shielded operating rooms has currently limited its availability to just a few centers (113, 130, 133, 148, 153, 154) .
Although brachytherapy is a very effective modality, case selection and proper patient evaluation are essential. If the tumor is very large or widely metastatic, one is doomed to fail due to the physics of dose distribution in the former case and due to the biology of the tumor in the latter case. There are some differences between various brachytherapy modalities (Table XVII) . These differences should be kept in mind when selecting the brachytherapy modality in a particular situation.
HDR has special relevance for developing countries where resources may be scarce. In this regard, the International Atomic Energy Agency (IAEA) has recently issued recommendations for the use of HDR brachytherapy in the developing countries (155). A brief summary is given here, however, readers interested in the details are referred to the original article (155). An HDR treatment system should be purchased as a complete unit that includes the 192 Ir radioactive source, source loading unit, applicators, treatment planning system, and control console. Infrastructure support may require additional or improved buildings and procurement of or access to new imaging facilities. A supportive budget is needed for quarterly source replacement and the annual maintenance necessary to keep the system operational. The radiation oncologist, medical physicist, and technologist should be specially trained before HDR can be introduced. Training for the oncologist and medical physicist is an ongoing process as new techniques or sites of treatment are introduced.
Procedures for quality assurance (QA) of patient treatment, and the planning system must be introduced. Emergency procedures with adequate training of all associated personnel must be in place. The decision to select HDR in preference to alternate methods of brachytherapy is influenced by the ability of the machine to treat a wide variety of clinical sites. In departments with personnel and budgetary resources to support this equipment appropriately, economic advantage becomes evident only if large numbers of patients are treated. With HDR it is possible to treat a large number of patients in institutions that have a high volume of brachytherapy patients but insufficient in-patient facilities for LDR brachytherapy or insufficient finances for the purchase of iodine-125 or palladium seeds for permanent implants. Intangible benefits of source safety, personnel safety, and easy adaptation to fluctuating demand for treatments also require consideration when evaluating the need to introduce this treatment system.
When HDR brachytherapy is used, the treatments must be executed carefully because the short treatment times do not allow any time for correction of errors, and mistakes can result in harm to patients. Hence, it is very important that all personnel involved in HDR brachytherapy be well trained and be constantly alert. However, with proper case selection and delivery technique, HDR brachytherapy has great promise and convenience because it eliminates radiation exposure, allows short treatment times, and can be preformed on an outpatient basis.
It is expected that the use of HDR brachytherapy will greatly expand over the next decade and that refinements will occur primarily in the integration of imaging (computed tomography, magnetic resonance imaging, intraoperative ultrasonography), and optimization of dose distribution (156, 157) . It is anticipated that better tumor localization and normal tissue definition will help to optimize dose distribution to the tumor and reduce normal tissue exposure (157).
The ability to readily integrate HDR brachytherapy and EBRT will result in increasing use of HDR brachytherapy in investigational protocols. Dose constraints of brachytherapy generally require that it follow maximal cytoreductive EBRT. However, with HDR it is increasingly possible to integrate brachytherapy earlier in the treatment course and emphasize the brachytherapy component.
Collaborative efforts among various institutions are needed to standardize the methodology and dose fractionation of HDR brachytherapy. The recognition of a need for consensus development has spurred the creation of the Clinical Research Committee of the American Brachytherapy Society. This committee has already published consensus guidelines (10) (11) (12) (13) (14) (15) (16) (17) (18) 84) . Further efforts are urgently required to form consensus opinions and standardization in HDR brachytherapy. The development of well-controlled randomized trials addressing issues of efficacy, toxicity, quality of life, and costs versus benefits will ultimately define the role of HDR brachytherapy in the therapeutic armamentarium. 
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